Leveraging our proprietary fully human antibody mice, including RenMice (RenMab, RenLite, and RenNano), we have cultivated a team of talented experts and established a fully integrated, one-stop solution from target validation to clinical studies. Our cutting-edge antibody discovery technologies, such as the Beacon Opto-Select single B cell antibody discovery technology, enable us to generate a high diversity of antibodies against a broad range of targets, including challenging ones like G-protein-coupled receptors, within a shortened timeline. Furthermore, our industry-leading genome targeting capability enables us to break immune tolerance by knocking out target genes, resulting in antibodies with cross-species binding specificity. This feature allows us to quickly screen for preclinical candidates of interest in wild-type laboratory mice and further validate them in larger animals such as companion pets, increasing the likelihood of translational success. Our platform also includes antibody engineering, developability assessment, and cell line and process development to ensure a seamless transition from early discovery to development stages. Our goal is to complete early discovery of over 1000 targets involved in human diseases within three years, addressing unmet needs and benefiting patients in need.

Platform Advantages 

1. RenMab mouse: 

RenMab mice carry fully human antibody variable domains, eliminating the need of antibody humanization. Natural in vivo selection and affinity optimization by the murine immune system generate antibodies with better physic-chemical propertiesand good drug like properties.

2. RenLite mouse: 

The common light chain antibody mice RenLite are better poised for the development of monovalent bispecifics. With a shared light chain, common technical challenges in bispecific antibody development like heavy-light chains mis-pairing and very poor developability issues are properly addressed.

3. RenNano mouse: 

RenNano mice provide very innovative solutions for single domain antibody discovery. Due to a much smaller size, single domain antibodies demonstrated better tissue penetration and the capability to cross blood-brain barrier.

4. Versatile antibody discovery toolkit: 

We deploy a versatile antibody discovery toolkit for fast antibody discovery with accerelated timeline, including Beacon Opto-Select-based single plasma cell antibody discovery, FACS-based single B cell sorting antibody discovery and in vitro display technologies like phage display.

5. Difficult targets: 

For difficult targets like GPCRs and ion channels, we build our success upon innovative antigen design, proprietary immunization strategies, fit-for-purpose antibody discovery and very comprehensive cell-based functional assays.

6. Cross-species binding specificity:

We break immune tolerance by target gene knockout in RenMab/RenLite/RenNano mice. Antibodies with cross-species binding specificity will be screened for in vivo functions in wild-type laboratory mice and be further validated in larger animals like companion pets for better translational success.

7. Antibody analytics and developability assessment:

We perform comprehensive antibody analytics and developability assays to nominate antibody hits with a higher development success rate.

8. Antibody engineering:

We have AI-assisted antibody engineering capability for fit-for-purpose engineering of antibodies such as affinity modulation, liability engineering, developability optimization, and effector function engineering.

9. Cell line development:

We have an industry-leading stable cell line development capability for higher yields and a shorter timeline.

Platform Capabilities